Guilford Gliadel Denied Add-On Payments By CMS; New IL-2 Code Proposed
Executive Summary
Guilford's Gliadel Wafer does not warrant add-on payments because the product's cost is already reflected in DRG weights, CMS says
You may also be interested in...
Zyvox Medicare “Add-On” Payments Denied; CMS Wary Of Precedent
The denial of Medicare "add-on" payments for Pharmacia's Zyvox reflects CMS' desire to avoid a precedent that could make numerous older therapies eligible for enhanced reimbursement, the agency said in an Aug. 1 final rule implementing changes to the hospital in-patient payment system
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials